File Download

There are no files associated with this item.

Supplementary

Conference Paper: Central administration of granulocyte-colony stimulating factor in a mice middle cerebral artery occlusion stroke model reduces infarct volume and improves functional outcome

TitleCentral administration of granulocyte-colony stimulating factor in a mice middle cerebral artery occlusion stroke model reduces infarct volume and improves functional outcome
Authors
Issue Date2007
PublisherSociety for Neuroscience
Citation
Neuroscience 2007, San Diego, CA, 3-7 November 2007, Program#/Poster#: 598.1/Z7 How to Cite?
AbstractGranulocyte-colony stimulating factor (G-CSF), a 20 kDa glycoprotein, has a role in promoting survival, proliferation and differentiation of hematopoietic cells. Recent studies have shown that G-CSF exhibits beneficial effects after cerebral ischemia. G-CSF may confer direct neuroprotection through its non-hematopoietic effects and/or indirect benefits via mobilization of the stem/progenitor cells from the bone marrow into the brain via peripheral blood. In this study, we aim to determine if G-CSF has any direct neuroprotective effects in the mice stroke model. Mice were subjected to transient focal middle cerebral artery occlusion (MCAO) for 60 minutes. A single dose of G-CSF (5 µg/kg, 1 µg/kg, 0.2 µg/kg) or vehicle (saline) at 1µL was given via an intrastriatal injection over 5 minutes commenced at the beginning of reperfusion. The WBC count in the peripheral blood was checked before and after (at 24 hr and 72 hr) the cytokine injection. The mice were decapitated at 72 hr and their brains were cut into 2-mm thick coronal slices before reaction with a 2% solution of 2,3,5-triphenyltetrazolium chloride to reveal the infarct. G-CSF did not change the peripheral WBC level at 24 hr and 72 hr (P>0.05 versus control). Treatment with G-CSF significantly reduced the infarct volumes at the doses of 5 µg/kg (34%, P<0.01) and 1 µg/kg (35%, P<0.01) but not 0.2 µg/kg (P>0.05). Also, better functional performances were seen in the G-CSF-treated groups in turning in an alley (5 µg/kg, P<0.05 and 1 µg/kg, P<0.05) as well as the hanging wire test (5 µg/kg, P<0.01 and 1 µg/kg, P<0.01) when compared with that in the vehicle-treated group. Our results indicate that G-CSF exerts direct neuroprotective effect through its non-hematopoietic effects, and further studies are needed to understand the mechanisms of this action.
Persistent Identifierhttp://hdl.handle.net/10722/102529

 

DC FieldValueLanguage
dc.contributor.authorChan, CFen_HK
dc.contributor.authorLeung, AYHen_HK
dc.contributor.authorChan, YSen_HK
dc.contributor.authorCheung, RTFen_HK
dc.date.accessioned2010-09-25T20:34:20Z-
dc.date.available2010-09-25T20:34:20Z-
dc.date.issued2007en_HK
dc.identifier.citationNeuroscience 2007, San Diego, CA, 3-7 November 2007, Program#/Poster#: 598.1/Z7-
dc.identifier.urihttp://hdl.handle.net/10722/102529-
dc.description.abstractGranulocyte-colony stimulating factor (G-CSF), a 20 kDa glycoprotein, has a role in promoting survival, proliferation and differentiation of hematopoietic cells. Recent studies have shown that G-CSF exhibits beneficial effects after cerebral ischemia. G-CSF may confer direct neuroprotection through its non-hematopoietic effects and/or indirect benefits via mobilization of the stem/progenitor cells from the bone marrow into the brain via peripheral blood. In this study, we aim to determine if G-CSF has any direct neuroprotective effects in the mice stroke model. Mice were subjected to transient focal middle cerebral artery occlusion (MCAO) for 60 minutes. A single dose of G-CSF (5 µg/kg, 1 µg/kg, 0.2 µg/kg) or vehicle (saline) at 1µL was given via an intrastriatal injection over 5 minutes commenced at the beginning of reperfusion. The WBC count in the peripheral blood was checked before and after (at 24 hr and 72 hr) the cytokine injection. The mice were decapitated at 72 hr and their brains were cut into 2-mm thick coronal slices before reaction with a 2% solution of 2,3,5-triphenyltetrazolium chloride to reveal the infarct. G-CSF did not change the peripheral WBC level at 24 hr and 72 hr (P>0.05 versus control). Treatment with G-CSF significantly reduced the infarct volumes at the doses of 5 µg/kg (34%, P<0.01) and 1 µg/kg (35%, P<0.01) but not 0.2 µg/kg (P>0.05). Also, better functional performances were seen in the G-CSF-treated groups in turning in an alley (5 µg/kg, P<0.05 and 1 µg/kg, P<0.05) as well as the hanging wire test (5 µg/kg, P<0.01 and 1 µg/kg, P<0.01) when compared with that in the vehicle-treated group. Our results indicate that G-CSF exerts direct neuroprotective effect through its non-hematopoietic effects, and further studies are needed to understand the mechanisms of this action.-
dc.languageengen_HK
dc.publisherSociety for Neuroscience-
dc.relation.ispartofSociety for Neuroscience Annual Meetingen_HK
dc.titleCentral administration of granulocyte-colony stimulating factor in a mice middle cerebral artery occlusion stroke model reduces infarct volume and improves functional outcomeen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailLeung, AYH: ayhleung@hku.hken_HK
dc.identifier.emailChan, YS: yschan@hkucc.hku.hken_HK
dc.identifier.emailCheung, RTF: rtcheung@hku.hken_HK
dc.identifier.authorityChan, YS=rp00318en_HK
dc.identifier.authorityCheung, RTF=rp00434en_HK
dc.identifier.hkuros149819en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats